{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:27Z","timestamp":1791313647161,"version":"4.3.1"},"reference-count":24,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1136\/bjophthalmol-2015-306790","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T22:28:09Z","timestamp":1442960889000},"page":"782-786","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":98,"title":["Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis"],"prefix":"10.1136","volume":"100","author":[{"given":"Elisabetta","family":"Miserocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Modorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Berchicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gerloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2015-306790-1","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ophtha.2009.05.002","article-title":"Epidemiology and course of disease in childhood uveitis","volume":"116","author":"Smith","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","article-title":"Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature","volume":"244","author":"Carvounis","year":"2006","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","article-title":"Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study","volume":"120","author":"Gregory","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-9071.2006.01225.x","article-title":"Biologic therapies for inflammatory eye disease","volume":"34","author":"Lim","year":"2006","journal-title":"Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-5","first-page":"1146","article-title":"Tumor necrosis factor-\u03b1 blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow up data from the Italian Registry","volume":"40","author":"Zannin","year":"2013","journal-title":"J Rheumatol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-9","first-page":"1","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"7","author":"Miserocchi","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"key-10.1136\/bjophthalmol-2015-306790-10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key-10.1136\/bjophthalmol-2015-306790-11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ncprheum0042","article-title":"B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus","volume":"2","author":"Eisenberg","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key-10.1136\/bjophthalmol-2015-306790-13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/bjo.2006.113316","article-title":"Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis","volume":"91","author":"Freidlin","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/bjophthalmol-2013-304686","article-title":"Treatment of diffuse subretinal fibrosis uveitis with rituximab","volume":"99","author":"Corrish","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-15","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.ophtha.2011.06.009","article-title":"Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective","volume":"118","author":"Joshi","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","article-title":"Rituximab for uveitis","volume":"118","author":"Miserocchi","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev"},{"key":"key-10.1136\/bjophthalmol-2015-306790-18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-19","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first International workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2015-306790-21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"key-10.1136\/bjophthalmol-2015-306790-22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0161-6420(01)00864-8","article-title":"Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2015-306790-23","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.24601","article-title":"Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis","volume":"60","author":"Barnes","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key-10.1136\/bjophthalmol-2015-306790-24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2015-306790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:50:24Z","timestamp":1601095824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2015-306790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,20]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1136\/bjophthalmol-2015-306790"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306790","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725804496.793563457","asserted-by":"object"}]},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}